Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride

Share Name	Share Symbol	Market	Type
Novo Nordisk	NYSE:NVO	NYSE	Common Stock

Share Name

Share Symbol

Market

Type

Novo Nordisk

NYSE:NVO

NYSE

Common Stock

	Price Change	% Change	Share Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	106.13				0	00:00:00

Price Change

% Change

Share Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

106.13

00:00:00

Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride

08/06/2009 1:00pm

PR Newswire (US)

Novo Nordisk (NYSE:NVO)
Historical Stock Chart

From Nov 2019 to Nov 2024

Click Here for more Novo Nordisk Charts.

NEW ORLEANS, June 8 /PRNewswire-FirstCall/ -- Novo Nordisk (NVO) data presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily liraglutide, taken as monotherapy, leads to statistically significant and sustained reductions in blood sugar and weight after two years of treatment. In the study, 58% of patients treated with liraglutide 1.8 mg once daily reached and maintained the ADA's blood sugar target of A1C less than 7% versus 37% of patients treated with glimepiride 8 mg once daily. "The fact that liraglutide continues to effectively lower blood sugar after two years of treatment is consistent with its other long-term clinical benefits such as continued reductions in fasting blood sugar and weight," said, Dr. Alan Garber, Baylor College of Medicine, Houston, a LEAD(TM) 3 principal study investigator. "Even with available treatments, many type 2 diabetes patients still struggle to control their blood sugar, while losing weight. Liraglutide represents an important advance for these patients." The LEAD(TM) 3 extension study also documented that treatment with liraglutide leads to early and lasting weight loss. Many currently available diabetes treatments lead to weight gain, a concern for type 2 diabetes patients, most of whom are already overweight. After two years of treatment with 1.8 mg of liraglutide, mean body weight decreased significantly (-2.7 kg) compared to overall weight increase in the glimepiride group (+1.1 kg). Hypoglycemia is a condition where blood sugar levels become too low. Minor hypoglycemia was more than six times less frequent in the liraglutide treatment groups compared with the glimepiride group. About LEAD(TM) 3 Extension The LEAD(TM) 3 Extension compared the efficacy and safety of liraglutide (1.8 mg and 1.2 mg, once daily) to glimepiride (8 mg, once daily) in patients with type 2 diabetes. Patients were treated previously with diet/exercise or low doses of one oral antidiabetic drug (OAD). The trial had a 52-week randomized, double-blind period followed by the one year extension; 59% entered the extension period of the trial and 43% of these patients completed the full two-year study period. LEAD(TM) 3: two-year data Two years Liraglutide Liraglutide Glimepiride monotherapy 1.8 mg, QD 1.2 mg, QD 8 mg, QD N=154 N=149 N=137 Diabetes duration, years at baseline 5.0 5.0 5.0 Previous treatment: % diet/exercise 35% 38% 34% % OAD monotherapy 65% 62% 66% A1C % at baseline 8.1 8.1 8.0 BMI, kg/m(2) at baseline 33 33 33 Change in A1C% from baseline -1.1 -0.9 -0.6 Change in A1C% from baseline (in patients with

	Real-time Prices	Level 2
London Stock Exchange
Chi-X Europe
BATS Europe
Aquis Exchange
FTSE Indices
Euronext
New York Stock Exchange
NASDAQ
American Stock Exchange
Dow Jones Indices
Forex
Precious Metal

London Stock Exchange
Advanced charts
Premium community
Data download

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

NVO Novo Nordisk